Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer-Reference-Cited by-同舟云学术

Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer

Published:2020-11 Issue: Volume:149 Page:33-40
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Liu Xiaoke^ORCID,Hong Lingzhi,Nilsson Monique,Hubert Shawna Marie^ORCID,Wu Shuhong^ORCID,Rinsurongkawong Waree,Lewis Jeffery,Spelman Amy,Roth Jack^ORCID,Swisher Steven,He Yong,Jack Lee J.,Fang Bingliang,Heymach John V.,Zhang Jianjun,Le Xiuning

Funder

China Scholarship Council

Calabresi Paul Award at MDACC

Rexanna Foundation

Khalifa Scholarship

Conquer Cancer Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference54 articles.

1. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

2. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc. Natl. Acad. Sci.,2004

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib;Lynch;N. Engl. J. Med.,2004

4. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial;Wu;Lancet Oncol.,2014

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is tumor microenvironment important for targeted therapy in lung cancer?;Cancer Letters;2024-11

2. Brain metastasis magnetic resonance imaging-based deep learning for predicting epidermal growth factor receptor (EGFR) mutation and subtypes in metastatic non-small cell lung cancer;Quantitative Imaging in Medicine and Surgery;2024-07

3. Osimertinib plus Chemotherapy versus Osimertinib for Patients with Advanced NSCLC Concomitant EGFR and TP53 Mutations: A Prospective Cohort Study;2024-06-11

4. Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect;Journal for ImmunoTherapy of Cancer;2024-06

5. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review;Advances in Therapy;2024-03-21